GLP-1 Drugs and Breast Cancer: What a 111,000-Woman Study Actually Shows — and What It Doesn't

The latest entry in the expanding catalogue of possible GLP-1 benefits landed at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2: women taking drugs like semaglutide (sold as Ozempic and Wegovy) appeared roughly 30% less likely to develop breast cancer than those who did not [1]. The finding, drawn from more than 111,000 medical records at Penn Medicine and simultaneously published in JCO Oncology Practice, generated immediate headlines. But behind the attention-grabbing number lies a chain of unanswered questions about causation, biology, and who stands to benefit.

The Penn Medicine Study: Design and Key Numbers

Led by Elizabeth McDonald, MD, PhD, a professor of radiology at the University of Pennsylvania Perelman School of Medicine, the study examined electronic health records of 111,646 women aged 45 to 80 with a BMI of 25 or above who had breast imaging and a documented outcome between January 2022 and June 2025 [1][2]. Of those women, 15,264 (13.7%) had documented GLP-1 prescriptions; the remaining 96,382 had no recorded exposure.

In the full cohort, GLP-1 users had about 35% lower odds of a breast cancer diagnosis. After propensity-score matching — a statistical technique that attempts to balance groups on observable characteristics like age, BMI, and comorbidities — the reduction was approximately 31% [1][3].

This was not the only study pointing in this direction. A separate nationwide analysis of 1.1 million patients on the TriNetX platform, published in early 2025, found that GLP-1 receptor agonist use was associated with reduced risk across multiple cancer types in people with obesity [4]. Semaglutide specifically showed a hazard ratio of 0.465 (95% CI 0.382–0.567) for breast cancer — meaning users appeared to have less than half the risk [4]. And preclinical work published in late 2024 showed that semaglutide slowed tumor growth and progression in a mouse breast cancer model by enhancing antitumor immunity [5].

Which Patients, Which Cancers?

The signal is not uniform. The Penn Medicine data showed the strongest association for hormone receptor-positive (HR+) breast cancer — the most common subtype and the one most clearly linked to obesity and estrogen exposure [6]. This is biologically plausible: excess body fat produces estrogen through aromatization, and postmenopausal women with higher BMI face roughly 12% greater risk of HR+ breast cancer per 5-point increase in BMI [7].

The TriNetX study's subgroup analyses found that females showed larger risk reductions than males (where breast cancer is rare), and that effects varied by specific GLP-1 drug [4]. However, neither study reported granular results by menopausal status, race, or diabetes status in sufficient detail to identify which subgroups see the most — or least — benefit.

The Biological Plausibility Question

Researchers have proposed several mechanisms through which GLP-1 drugs might affect cancer biology directly, beyond their well-known effects on weight:

• Anti-proliferative signaling: GLP-1 receptor activation triggers intracellular cascades that may suppress tumor cell proliferation and promote apoptosis (programmed cell death) [8].
• Immune modulation: Semaglutide enhanced acquired antitumor immunity in mouse models, accelerating immune recognition of cancer cells [5].
• Anti-inflammatory effects: GLP-1 drugs reduce systemic inflammation, which is implicated in cancer development. Obesity produces chronic low-grade inflammation that may create a favorable microenvironment for tumor growth [8][1].
• Metabolic regulation: The drugs improve insulin sensitivity and reduce circulating insulin levels. Hyperinsulinemia — excess insulin in the blood — is itself associated with increased breast cancer risk [8].

However, the picture is not entirely clean. A 2022 study found that liraglutide, an older GLP-1 receptor agonist, actually promoted progression in triple-negative breast cancer cells through an oxidative stress pathway [8]. And a recent paper in a cancer journal found that GLP-1 targeting agents impaired the effectiveness of chemoimmunotherapy in triple-negative breast cancer [9]. These findings underscore that the relationship between GLP-1 signaling and cancer is more complicated than "drug reduces risk."

The Obesity Connection

Obesity is the elephant in the room of every GLP-1 cancer study. The United States has the highest adult obesity prevalence among major economies at 41% [10], and obesity is an established risk factor for at least 13 types of cancer, including postmenopausal breast cancer [7].

Source: WHO Global Health Observatory

Data as of Dec 31, 2024CSV

The central confound: GLP-1 drugs produce substantial weight loss — 15 to 20% of body weight in clinical trials of semaglutide. Weight loss itself reduces breast cancer risk. Bariatric surgery, which produces comparable weight loss through a completely different mechanism, is associated with roughly 40% reduction in postmenopausal breast cancer risk [7]. So how much of the GLP-1 signal is the drug, and how much is the weight loss?

Neither the Penn Medicine study nor the TriNetX analysis could answer this. As the Penn Medicine team acknowledged, patient-level weight change data were unavailable, so the analysis "cannot explain whether observed differences were driven by weight loss, metabolic control, cardiovascular effects, direct tumor biology, or differences in patient selection" [2][3].

How Does 31% Compare?

Placing the observed 31% risk reduction in context against established breast cancer prevention interventions:

Source: Multiple sources (ACS, NCI, ASCO 2026)

Data as of Jun 3, 2026CSV

Prophylactic bilateral mastectomy reduces risk by approximately 90% but is an irreversible surgical procedure typically reserved for women with very high genetic risk [11]. Tamoxifen, a selective estrogen receptor modulator used for chemoprevention in high-risk women, reduces invasive breast cancer risk by about 49%; raloxifene by about 38% [11]. Bariatric surgery is associated with roughly 40% reduction [7]. Sustained weight loss through diet and exercise — a 5-point BMI reduction — is associated with approximately 12% lower risk in postmenopausal women [7].

If the 31% figure holds up in prospective trials, GLP-1 drugs would sit in a meaningful range — less effective than tamoxifen but potentially more accessible and with broader health benefits. The "if" is doing significant work in that sentence.

The Skeptics' Case

The criticism from independent researchers has been pointed. A separate study on GLP-1 drugs and breast cancer survival — which reported a 91% reduction in mortality risk — drew a blunt assessment from Dr. Simon Vincent, chief scientific officer at Breast Cancer Now: "the headline results reported in this paper seems too good to be true" [12][13].

Experts at the UK Science Media Centre identified several specific problems [13]:

Confounding by indication and healthy-user bias: "Individuals motivated to take GLP-1 receptor agonists may also be those more engaged in improving their health overall, meaning other lifestyle behaviours are likely more favourable and could explain the associations observed" [13]. Women who can access GLP-1 drugs tend to be wealthier, more engaged with healthcare, and more likely to receive regular screening — all of which independently correlate with better cancer outcomes.

Incomplete data: In the survival study, estrogen receptor status was known for only about 20% of the population, versus the near-100% expected in well-curated oncology datasets. The proportion of patients with DCIS (ductal carcinoma in situ) was 8-10% versus an expected 15-20% [13].

Immortal time bias: A methodological flaw where individuals who received GLP-1 drugs at any point after a cancer diagnosis were classified as GLP-1 users, even if they started the drug long after diagnosis. This creates a structural advantage for the drug group, because patients who died early never had the opportunity to be prescribed the medication [12][13].

Cardiovascular confounding: As one expert noted, "most women with breast cancer don't die of breast cancer, they die of heart disease." GLP-1 drugs have proven cardiovascular benefits, so apparent cancer survival advantages may partly reflect fewer cardiac deaths rather than direct anticancer effects [13].

A methodological critique published in a peer-reviewed journal specifically addressed "methodological pitfalls in observational studies" of GLP-1 drugs and cancer prevention, cataloguing the ways these study designs can produce misleadingly strong associations [14].

The Access and Equity Problem

GLP-1 drugs in the United States cost approximately $936 per month — compared to $93 in the United Kingdom and $51 in Croatia [15]. Insurance coverage for obesity treatment (as opposed to diabetes) remains inconsistent. Without comprehensive insurance, "significant disposable income is required to afford these medications," as researchers noted in a study on GLP-1s and health inequality [15].

This creates an uncomfortable dynamic: if GLP-1 drugs do reduce breast cancer risk, the benefit accrues primarily to patients who can afford them. Black women, who already face higher breast cancer mortality rates than white women, are disproportionately likely to lack access [15]. The 2023-2024 semaglutide shortage, driven partly by off-label demand from affluent patients seeking weight loss, "critically reduced access to a vulnerable patient group: those with type 2 diabetes, who are often from lower-income and minority backgrounds" [15].

There is some movement on the policy front. Beginning July 1, 2026, the Centers for Medicare & Medicaid Services will provide eligible Medicare beneficiaries access to certain GLP-1 medications for $50 per month through the Medicare GLP-1 Bridge program, running through December 2027 [16]. But this covers only Medicare recipients and remains a temporary measure.

If cancer-prevention messaging begins to emphasize GLP-1 drugs before prospective trial evidence exists, resources and attention could shift away from proven, accessible interventions — regular physical activity, maintaining healthy weight through diet, and chemoprevention with generic tamoxifen (which costs a fraction of GLP-1 drugs) — toward an expensive option out of reach for many at-risk women.

What Would It Take to Prove Causation?

The gap between "associated with" and "causes" is where the real scientific work remains. What oncologists and epidemiologists say is needed [12][13][14]:

1. A prospective randomized controlled trial — not a retrospective database analysis — that randomly assigns high-risk women to GLP-1 treatment or placebo and follows them for breast cancer incidence. The Penn Medicine team has signaled plans for a multi-site clinical trial [1].

2. Adequate follow-up duration: Breast cancer develops over years to decades. The Penn Medicine study covered a roughly 3.5-year window. A meaningful prevention trial would need 5 to 10 years of follow-up.

3. Weight-change data: Any future study must track body weight longitudinally to disentangle the drug's direct effects from weight-loss-mediated effects.

4. Diverse patient enrollment: Given the access disparities, trials must actively recruit across racial, socioeconomic, and insurance-status lines.

5. Sample size: The absolute number of breast cancer cases in GLP-1 users in existing studies is relatively small. A prospective trial would need thousands of participants to detect a clinically meaningful difference with statistical confidence.

Until such a trial reports results, the appropriate clinical response is not to prescribe GLP-1 drugs for breast cancer prevention, but to recognize the signal as hypothesis-generating — a reason to investigate further, not a reason to change practice.

A Research Field in Rapid Expansion

The volume of scientific literature at the intersection of GLP-1 drugs and breast cancer has grown sharply. Academic publications on this topic peaked at 2,153 papers in 2025, with 864 published in the first half of 2026 alone [17].

Source: OpenAlex

Data as of Jan 1, 2026CSV

This surge reflects both genuine scientific interest and the commercial stakes involved. Novo Nordisk (maker of Ozempic and Wegovy) and Eli Lilly (maker of tirzepatide, sold as Mounjaro and Zepbound) are among the most valuable pharmaceutical companies in the world, and any credible cancer-prevention indication would massively expand their addressable market.

The Bottom Line

The Penn Medicine study adds to a growing body of evidence suggesting that GLP-1 drugs are associated with lower breast cancer incidence, particularly for hormone receptor-positive tumors in women with overweight or obesity. The biological mechanisms are plausible. The signal is consistent across multiple datasets.

But "associated with" is not "causes." The studies to date are observational, lack weight-change data, and are vulnerable to the kind of selection biases that can make a merely correlated finding look causal. The patients who take GLP-1 drugs are systematically different from those who do not — in wealth, health engagement, and access to care — in ways that no statistical adjustment can fully resolve.

For women concerned about breast cancer risk today, the evidence-based toolkit remains what it was before ASCO 2026: maintain a healthy weight, exercise regularly, discuss chemoprevention with a physician if at high risk, and stay current on screening. GLP-1 drugs may eventually join that list. The evidence is not there yet.